Elevating Lead Compounds through Lead Optimization
Lead compounds are molecules that demonstrate promising activity against a target disease or condition, during the early stages of drug discovery. However, these initial compounds often need refinement to enhance their attributes, and address potential drawbacks - our lead optimization service will resolve these issues.
With us, you can modify lead compounds to improve drug-like properties and minimize undesirable effects, this optimization process involves enhancing parameters such as potency, selectivity, pharmacokinetics, and safety profiles.
Lead Optimization Services: Key Aspects
Structure-Activity Relationship (SAR) Analysis: correlation between a compound’s chemical structure and its biological activity, through systematic modifications to specific chemical groups, researchers can determine the impact of structural changes on the compound’s potency and selectivity. SAR analysis assists in the iterative compound optimization process.
PK PD and Toxicity Studies: Assessing the absorption, distribution, metabolism, and excretion of a compound is an integral part of our lead optimization service. Identification of potential issues early on, modify the compound’s structure to achieve optimal drug-like properties. Additionally, toxicity studies are conducted to ensure the compound’s safety for human use, beyond efficacy, optimization encompasses various aspects of a compound’s behaviour and characteristics.
Biological Evaluation and In Vivo Assays: Rigorous testing is conducted on lead compounds against the target disease or condition using various biological assays, these assays offer insights into the compound’s mechanism of action and its effect on disease-related pathways. Through iterative testing, the characteristics of the lead compound can be refined to attain desired therapeutic outcomes.
Optimizing Lead Discovery Compounds
Through our lead optimization you will have access to a wide range of pharmacology services that will help with the lead optimization of your drug candidate:
PK PD Services
Providing valuable insights into drug-induced behavioral or psychological effects in living organisms, PK PD studies seamlessly incorporate numerous assays to meet your specific requirements and needs.
With a focus on in vivo toxicity testing, small molecule, biologics, and cell-therapy programs, we offer a range of toxicology studies and services to support drug development.
In Vivo Disease Models
Advance and accelerate preclinical research with our in vivo disease models, including oncology, ophthalmology, NASH, and geriatric models.
As part of our lead optimization support, histology provides insights into the effects of lead compounds on biological systems, which will aid the refinement of drug candidates for optimal pharmacological properties.
Cell-based assays provide a comprehensive understanding of how lead compounds interact with living cells, understand their efficacy, selectivity, and potential therapeutic impact.
Our Biophysical Assays in Lead Optimization Services
Harness state-of-the-art biophysical assays through our lead optimization services, which will provide a comprehensive understanding of molecular interactions, accelerating the refinement of your potential drug candidates.
Surface Plasmon Resonance Services (SPR)
SPR is an optical technique that monitors interactions between biomolecules, providing information on binding kinetics, affinity, and specificity of molecular interactions, a pivotal technique in our lead optimization.
Bio-Layer Interferometry Services (BLI)
The high-throughput kinetic screening technique, BLI, measures the biomolecular interactions of proteins, peptides, and nucleic acids in complex matrices.
Isothermal Titration Calorimetry (ITC)
ITC provides quantitative information on the thermodynamics of molecular interactions. Examining the binding affinity, stoichiometry, profile of lead compounds and interactions with target biomolecules.
Nuclear Magnetic Resonance Services (NMR)
Our NMR services investigate the structural characteristics, interactions, dynamic behaviour of molecules, which will reveal the three-dimensional structure of molecules, driving the refinement of lead compounds.
Lead Optimization Services Tailored to You
Extending beyond a standard transactional relationship our lead optimization assistance will foster a collaborative partnership, we will work closely with you to align our efforts with your drug discovery goals. Your insights, expertise, and vision becomes integral to the overall optimization journey, ensuring that the lead candidates are tailored to your specific objectives.
Customization and Flexibility
Our lead optimization capabilities offer customization and flexibility to cater to your specific needs, we recognize that every drug discovery project is unique, which demands a tailored approach. Whether it’s the choice of assays, the frequency of updates, or the focus on specific attributes, we tailor our services to align with your project’s needs.
Are you ready to optimize your drug discovery journey?
Unlock faster decision-making and enhance drug-like properties with our lead optimization services.
We prioritize your success and approach everything with a scientific perspective. We collaborate with you at all times to ensure the selection of the appropriate models and analytical end-points to address your specific questions. Engaging on a program level, we design tailored lead optimization services to meet your needs.
What additional services can I expect during the lead optimization process?
ADME profiling, computational ADMET predictions, formulation and delivery strategies, PK/PD modelling and simulation, molecular design, biomarker identification, regulatory guidance, target engagement assays and more are all part of our extensive lead optimization services.
Where are you based?
We are a US-based company and we don’t outsource our lead optimization. When you work with us, you can trust that all of your work is getting completed within the United States.
Recombinant Manganese Peroxidase Reduces A2E Burden in Age-Related and Stargardt's Macular Degeneration Models
Coevolution of the Ess1-CTD axis in polar fungi suggests a role for phase separation in cold tolerance